. "Appendix F: Examples of Pharmaceutical Company Training Programs." Opportunities to Address Clinical Research Workforce Diversity Needs for 2010. Washington, DC: The National Academies Press, 2006.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Opportunities to Address Clinical Research Workforce Diversity Needs for 2010
Bristol-Myers Squibb
1. Name of Program: Fellowship Program in Academic Medicine for Minority Students
Population: First- through third-year students. U.S. citizens who are African American, mainland Puerto Rican, Mexican American, or American Indian (Alaska Native, Native Hawaiian); M.D.-degree-granting medical school in the United States
Program Description:
To address a simple but significant statistic: minorities are profoundly underrepresented in the field of academic medicine
2. Name of Program: Freedom to Discover Grants and Awards
Population: Institutions and principal investigators: cancer grant recipients, cardiovascular grant recipients, infectious diseases grant recipients, metabolic grant recipients, neuroscience grant recipients, and nutrition grant recipients
Program Description:
To provide relief and even cures from devastating and debilitating illnesses to millions of people around the world
Length of Award: Five years
Amount Awarded: $500,000 unrestricted research grant and a distinguished achievement award of $50,000 to an individual researcher
Pharmaceutical Industry Setting: To receive balanced instruction in service, education, and research
Institutional Setting: To gain important experience in the provision of drug information within the acute care setting, including participation in the Pharmacy and Therapeutics Committee and the Institutional Review Board
Population: Pharm.D., Ph.D., M.D., or master’s degree
Program Objective:
To fully develop individuals into effective, influential professionals knowledgeable about the drug development process and the pharmaceutical industry